Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF NOVEMBER 07, 2010 FBO #3270
SOLICITATION NOTICE

R -- NIMH NeuroAIDS Therapeutic Initiative

Notice Date
11/5/2010
 
Notice Type
Presolicitation
 
NAICS
541990 — All Other Professional, Scientific, and Technical Services
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
 
ZIP Code
20892
 
Solicitation Number
NOI-1838880
 
Archive Date
12/4/2010
 
Point of Contact
Liem T Nguyen, Phone: 3014358780
 
E-Mail Address
ln18x@nih.gov
(ln18x@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
The National Institute on Drug Abuse (NIDA), Office of Acquisitions Station Support Simplified Acquisitions Branch on behalf of the National Institute of Mental Health (NIMH) intends to negotiate and award a purchase order, on a non-competitive basis, to Dr. Deborah Ann (Bravo) Colosi, 6218 Wagner Lane, Bethesda, MD 20816, for professional services in support the NIMH's NeuroAIDS Therapeutic Initiative. This acquisition will be made pursuant to the authority of FAR 13.106-1(b)(1). The North American Industry Classification System Code is 541990 and the business size standard is $7.0 million. Therapeutic approaches have realized much success in managing HIV/AIDS, however strategies to prevent or treat the neurological complications that frequently accompany HIV disease have been less successful. This is due to limited availability of drugs across the blood brain barrier, the high degree of toxicity that accompanies long term use of current antiretroviral drugs, and the co-morbid mental health conditions that frequently accompany HIV/CNS disease, such as depression, anxieties, mood disorders, as well as others. While the extreme manifestations of AIDS dementia complex have decreased in frequency, less severe but nevertheless debilitating neurological complications persist. This is particularly important as individuals with HIV are living longer with compromised ability to function, also exacerbated by the normal aging processes in an increasing proportion of this population. The National Institute of Mental Health (NIMH) Center for Mental Health Research on AIDS (CMHRA) proposes to expand the therapeutics program by developing several initiatives to identify new therapeutic targets emerging from basic HIV neuropathogenesis research, and foster the pre-clinical and clinical testing of these drugs through mechanisms supportive of these approaches. The vendor shall perform the following tasks: 1. Develop several funding announcements which are part of an integrated strategy to expand on the development and testing of new therapeutic agents for the prevention and treatment of the neurological consequences of HIV/CNS disease. 2. Respond to writing or report requests from the NIMH Office of Director or other requesters relating to the NeuroAIDS portfolio as needed. This includes, but is not limited to, responding to congressional writing requests from OD relating the NeuroAIDS portfolio and Trans-NIH therapeutic information requests. 3. Grant or contract related write-ups as needed. This includes, but is not limited to, scientific justifications for Form 1820, professional services contracts, consultant agreements, administrative supplement justifications, brief summaries of grants marked for interest in preparation for pre-council meetings, concept and Program initiative write-ups. 4. Research, planning, coordination and implementation of Program development, conferences and workshops as needed. These include scientific conferences as well as meetings with multi-site projects (NNTC, CHARTER). The contractor will conduct the background research for these announcements, and consult with the COTR weekly to discuss current scientific approaches, ongoing clinical trials, and optimal strategies that should be incorporated into these announcements. During these meetings, the PO will assess progress and make suggestions. The duration of these meetings with the COTR might last up to 3 hours. In addition, the contractor will assist Program in the implementation and management of the next phase of these contracts with the NNTC. Finally, the contractor will provide technical and scientific assistance to the COTR in management of the applications that arrive in response to the FOAs. This includes assisting in programmatic review of the science proposed in the applications and assisting in the management of the applications which are selected by peer review for funding. Dr. Colosi has more than 5 years experience working as a Senior Research Scientist at Bayer HealthCare Pharmaceuticals. During that time, she participated in all aspects of the process of moving drugs from bench to bedside. This includes developing and overseeing the protocols and strategies for testing and assessing the effectiveness of specific drugs as well as reviewing progress and making recommendations for future work. This experience has given her a good understanding of the science and process necessary to move therapeutic agents from bench to bedside. In addition Dr. Colosi has a strong background in basic science, including biochemistry and virology, as seen by her doctoral and post-doctoral research experience, which is essential to understand the complexities of targeting therapeutic interventions to HIV-mediated cell dysfunction. The Division of AIDS Research currently lacks this expertise in the drug development process and yet the need for a strong programmatic approach to the therapeutics in NeuroAIDS is critical. Dr. Colosi brings scientific and drug-company expertise to this effort, which is currently not available among the program staff of the NIMH-DAR. Dr. Colosi has been researching the current state of therapeutic approaches to managing HIV/CNS disease over the past 12 months and has written an extensive review of this area. In addition, she has convened a meeting with some of the leaders in the field to review our current efforts and develop a set of recommendations for next steps. Given the extent of her knowledge, Dr. Colosi is considered uniquely positioned to move the NIMH's proposed approaches to the next phase. Not only does this initiative require knowledge of the field, but it also requires an understanding of existing programs at NIMH in order to leverage resources and maximize use of limited funds. Dr. Colosi has had past experiences with the workshops that she convened. Dr. Colosi's previous work for the NIMH has been outstanding and her continuation is critical to the development of this important program to improve the lives of individuals living with HIV. It is determined that Dr. Colosi is the only known source qualified to perform the required services. No other sources will satisfy the agency's requirement. The period of performance is to be ten (10) months from date of award. Place of performance is to be at the NIH main campus located in Bethesda, Maryland 20892. This is a fee-for-service type acquisition. This is not a solicitation for competitive quotations. However, interested party may submit a statement of capabilities on or before 1:00 PM E.T., November 19, 2010 to Liem T Nguyen, ln18x@nih.gov. All information furnished must be in writing and must contain sufficient detail to allow the NIDA/NINDS to determine if it can meet the above unique specifications described herein. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NIDA vendor must be registered in the Online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov. In addition, vendor must be registered in the Central Contractor Registration (CCR) at www.ccr.gov. Please reference announcement number NOI-1838880 on all correspondence.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-1838880/listing.html)
 
Place of Performance
Address: Bethesda, Maryland, 20892, United States
Zip Code: 20892
 
Record
SN02323539-W 20101107/101105234152-4c169cf36b170928e583f3d69694281f (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.